GRAIL, LLC

Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. and is urging investors who suffered substantial losses to seek lead plaintiff status by the August 4, 2026 deadline. The lawsuit alleges that GRAIL and certain senior executives misled investors about the clinical design and efficacy of its NHS-Galleri cancer screening trial, claiming the three-year follow-up period was sufficient to show a statistically significant reduction in late-stage cancer diagnoses while concealing internal indicators that a longer timeline was needed. On February 19, 2026, GRAIL disclosed that the trial failed to meet its primary endpoint and admitted it probably should have allowed for a longer follow-up period, causing shares to plummet 50.55% from $101.53 to $50.21 in a single session and erasing over $2.2 billion in market capitalization. The firm is also investigating when management first recognized the divergence from the touted three-year duration, and encourages whistleblowers with non-public information to come forward.

The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Badger Meter, PicS N.V., Verra Mobility Corporation, and Grail, Inc., with lead plaintiff deadlines approaching in early August 2026. The Badger Meter suit, with a deadline of August 3, 2026, alleges the company concealed weakening demand by pulling forward customer orders to recognize revenue early. The PicS N.V. action, deadline August 4, 2026, claims the company's IPO offering documents failed to disclose deficient credit evaluation procedures and a reclassification of approximately R$590 million of exposures, leading to an incremental expected credit loss charge of R$88 million. Verra Mobility, also with an August 4 deadline, is accused of misleading investors about its reliance on a contract extension with Avis Budget for continued growth. Grail, Inc., with the same August 4 deadline, allegedly misrepresented the sufficiency of data from its trial's first screening round and Pathfinder studies to demonstrate the achievability of a primary endpoint. Investors who suffered losses can contact the firm to discuss their legal rights.

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against GRAIL, Inc. and that the deadline to seek lead plaintiff appointment is August 4, 2026. The lawsuit, filed in the United States District Court for the Northern District of California, covers purchasers of GRAIL common stock between May 13, 2025 and February 19, 2026. The complaint alleges that defendants made materially false and misleading statements and concealed adverse facts about the NHS Galleri trial, including that the trial period was insufficient to demonstrate the primary endpoint of a statistically significant reduction in Stage III-IV cancers. On February 19, 2026, GRAIL announced that the primary endpoint was not observed, causing its stock price to fall significantly. Investors who suffered losses can contact the firm's partners Brandon Walker or Melissa Fortunato at (212) 355-4648 or investigations@bespc.com.

Holzer & Holzer, LLC reminds investors of the August 4, 2026 lead plaintiff deadline in a securities class action against Grail, Inc. The lawsuit alleges that Grail made false and misleading statements about the probability of achieving the primary endpoint in its NHS-Galleri trial. Shareholders who purchased Grail shares between May 13, 2025 and February 19, 2026 and suffered losses may contact the firm to discuss their legal rights.

Robbins Geller Rudman & Dowd LLP announced that investors who purchased Grail common stock between May 13, 2025 and February 19, 2026 have until Tuesday, August 4, 2026 to seek appointment as lead plaintiff in a securities class action lawsuit against the company. The lawsuit alleges that Grail and certain executives made false or misleading statements about the likelihood of achieving the primary endpoint in its NHS-Galleri cancer screening trial, concealing adverse facts that reduced the probability of success. On February 19, 2026, Grail disclosed that the trial did not meet its primary endpoint of a statistically significant reduction in late-stage cancers, causing its stock price to drop more than 50%. The case, captioned Robbins v. Grail, Inc., was filed in the Northern District of California under the Securities Exchange Act of 1934.

Bernstein Liebhard LLP reminds GRAIL, Inc. investors that the deadline to join a securities fraud class action lawsuit is August 4, 2026. The lawsuit, filed on behalf of investors who purchased or acquired GRAIL common stock between May 13, 2025 and February 19, 2026, alleges that the company and certain senior officers made materially false and misleading statements about its business operations, growth prospects, and financial stability, causing shares to trade at artificially inflated prices. Investors who suffered losses are encouraged to submit a form or contact Investor Relations Manager Peter Allocco before the deadline. Those wishing to serve as lead plaintiff must file papers by August 4, 2026, though participation in any recovery does not require serving as lead plaintiff.

Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc., alleging the company misled investors about the design and efficacy of its NHS-Galleri cancer screening trial. The suit covers investors who purchased GRAIL common stock between May 13, 2025 and February 19, 2026, with a lead plaintiff deadline of August 4, 2026. The complaint claims GRAIL and senior executives touted a three-year follow-up period as sufficient to show a statistically significant reduction in late-stage cancer diagnoses, while concealing internal indicators that a longer timeline was needed. On February 19, 2026, GRAIL disclosed the trial failed to meet its primary endpoint and admitted it probably should have allowed for a longer follow-up, causing shares to plummet 50.55% from $101.53 to $50.21 in a single session and erasing over $2.2 billion in market capitalization. Hagens Berman is also investigating when management first knew the three-year timeline was inadequate.

Rosen Law Firm reminds purchasers of GRAIL, Inc. common stock during the class period from May 13, 2025 to February 19, 2026 of the August 4, 2026 lead plaintiff deadline in a securities class action. If you purchased GRAIL common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The lawsuit alleges that defendants made materially false and misleading statements and concealed adverse facts about the NHS-Galleri trial, including that the trial period was insufficient to demonstrate a reduction in Stage III-IV cancers. Investors with losses exceeding $100,000 are encouraged to secure counsel before the deadline. More information is available at rosenlegal.com.

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against GRAIL, Inc. and that the deadline to seek lead plaintiff appointment is August 4, 2026. The lawsuit, filed in the United States District Court for the Northern District of California, covers purchasers of GRAIL common stock between May 13, 2025 and February 19, 2026. The complaint alleges that defendants made materially false and misleading statements and concealed adverse facts about the NHS Galleri trial, including that the trial period was insufficient to demonstrate a reduction in Stage III-IV cancers. On February 19, 2026, GRAIL announced that the primary endpoint of statistically significant Stage III-IV reduction was not observed, causing the stock price to fall significantly. Investors who suffered losses can contact the firm's partners Brandon Walker or Melissa Fortunato at (212) 355-4648 or investigations@bespc.com.

Glancy Prongay Wolke & Rotter LLP reminds Grail, Inc. shareholders of an August 4, 2026 deadline to move for lead plaintiff in a class action covering purchases of Grail common stock between May 13, 2025 and February 19, 2026. The suit follows Grail's February 19, 2026 disclosure that its NHS-Galleri Trial did not meet the primary endpoint of statistically significant Stage III-IV cancer reduction, partly because longer follow-up may be needed. On that news, Grail's stock fell $51.32, or 50.5%, to close at $50.21 per share on February 20, 2026. The complaint alleges that defendants made materially false or misleading statements and failed to disclose that management's confidence in earlier positive top-line results ignored trendlines suggesting three years would be insufficient to demonstrate the primary endpoint.

Holzer & Holzer, LLC has announced upcoming deadlines for investors to seek lead plaintiff appointment in shareholder class action lawsuits against Badger Meter, Grail, and Verra Mobility. The Badger Meter lawsuit covers purchases between April 18, 2024 and April 16, 2026, with a lead plaintiff deadline of August 3, 2026. The Grail lawsuit covers purchases between May 13, 2025 and February 19, 2026, and the Verra Mobility lawsuit covers purchases between February 24, 2026 and May 26, 2026, both with a lead plaintiff deadline of August 4, 2026. Investors who suffered losses are encouraged to contact the firm.

National shareholder rights firm Hagens Berman is investigating claims in a pending securities class action against GRAIL, Inc. alleging the company misled investors about the clinical design and efficacy of its NHS-Galleri cancer screening trial. The lawsuit, covering a class period from May 13, 2025 to February 19, 2026, contends GRAIL concealed that its three-year follow-up period was insufficient to meet the primary endpoint of a statistically significant reduction in late-stage cancer diagnoses. On February 19, 2026, GRAIL disclosed the trial failed that endpoint and admitted it probably should have allowed a longer follow-up, causing shares to drop approximately 50.55% and erasing over $2.2 billion in market capitalization. Investors who suffered substantial losses have until August 4, 2026 to seek lead plaintiff appointment.

The Gross Law Firm has issued a shareholder alert for GRAIL, Inc., setting an August 4, 2026 deadline for investors to seek lead plaintiff appointment in a securities class action. The class period runs from May 13, 2025 to February 19, 2026, covering allegations that the company made false and misleading statements about its NHS-Galleri trial. On February 19, 2026, GRAIL announced the trial's primary endpoint of a statistically significant reduction in Stage III-IV cancers was not observed, causing its stock to plummet from $101.53 to $50.21 per share in a single day, a decline of about 50.55%. Shareholders who purchased GRAL shares during the class period are encouraged to register for the action, with no cost or obligation to participate.

The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Badger Meter, PicS N.V., Verra Mobility Corporation, and Grail, Inc., with lead plaintiff deadlines approaching in early August 2026. For Badger Meter, the class period runs from April 18, 2024 to April 16, 2026, and the deadline is August 3, 2026; the complaint alleges the company pulled forward customer orders to recognize revenue early, concealing weakening demand. PicS N.V., whose class period covers its January 2026 IPO, faces an August 4, 2026 deadline, with allegations that offering documents failed to disclose deficient credit evaluation procedures and a reclassification of approximately R$590 million of exposures leading to an incremental expected credit loss charge of R$88 million. Verra Mobility's class period spans February 24, 2026 to May 26, 2026, with an August 4, 2026 deadline, and the complaint claims the company's growth outlook was dependent on a contract extension with Avis Budget while minimizing risks of replacement. Grail, Inc.'s class period is May 13, 2025 to February 19, 2026, also with an August 4, 2026 deadline, and the suit alleges management misplaced confidence in trial results and ignored data suggesting the primary endpoint might not be met. Investors who suffered losses can contact the firm to discuss their legal rights.

Grail stock plunged more than 50% in February after its landmark NHS-Galleri trial failed to meet the primary endpoint of a statistically significant reduction in late-stage cancer detection, though a favorable trend was seen in a pre-specified group of 12 deadly cancers. The multi-cancer early detection test Galleri is already available as a Laboratory Developed Test and can be purchased out of pocket, but the real catalyst for the stock will be FDA approval and subsequent adoption by insurers including Medicare. Management is working to release more detailed trial data and negotiate a 12-month follow-up to potentially prove the test's value, while emphasizing Galleri's higher sensitivity for the 12 deadly cancers. Insurers will ultimately need to weigh the cost-effectiveness of catching these cancers early against the expense of the test and follow-up procedures for false positives. Early investors Jeff Bezos and Bill Gates backed Grail before it was bought by Illumina in 2021 and spun off in 2024.

Rosen Law Firm reminds purchasers of GRAIL common stock between May 13, 2025 and February 19, 2026 of the August 4, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that defendants made materially false and misleading statements and concealed adverse facts about the NHS-Galleri trial, including that the trial period was insufficient to demonstrate a reduction in Stage III-IV cancers and that detailed topline results were withheld. Investors who purchased shares during the class period may be entitled to compensation through a contingency fee arrangement without out-of-pocket costs. A lead plaintiff must move the Court by August 4, 2026.

Faruqi & Faruqi, LLP reminds investors of the August 4, 2026 deadline to seek lead plaintiff in a securities class action against Grail, Inc. The lawsuit alleges that Grail and its executives made false and misleading statements about the likelihood of success of its NHS-Galleri cancer detection trial, touting confidence in its effectiveness while concealing that the trial period was likely insufficient to achieve the primary endpoint of a statistically significant reduction in Stage III and IV cancers. On February 19, 2026, Grail announced the primary endpoint was not observed, causing its stock price to fall from $101.53 to $50.21 per share, a decline of about 50.55% in a single day. Investors who purchased or acquired Grail securities between May 13, 2025 and February 19, 2026 may be eligible to participate.

A securities fraud class action has been filed against GRAIL, Inc. and certain senior executives following a 50.55% stock drop on February 20, 2026. The lawsuit, pending in the U.S. District Court for the Northern District of California, alleges that GRAIL made misleading positive statements about its NHS-Galleri cancer screening trial, including that the three-year trial design was sufficient to achieve the primary endpoint of reducing late-stage cancers. On February 19, 2026, GRAIL disclosed that the trial did not meet that endpoint, attributing the shortfall partly to a need for longer follow-up, which caused shares to fall from $101.53 to $50.21. Investors have until August 4, 2026 to seek lead plaintiff appointment.

Holzer & Holzer reminds investors of upcoming lead plaintiff deadlines in shareholder class action lawsuits against Badger Meter, Grail, and PicS. The Badger Meter suit, covering purchases between April 18, 2024 and April 16, 2026, has a deadline of August 3, 2026. The Grail case, for shares bought from May 13, 2025 to February 19, 2026, and the PicS case, related to its January 2026 IPO, both have an August 4, 2026 deadline. Investors who suffered losses are encouraged to contact the firm.

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of Badger Meter, PicS, Verra Mobility, and Grail, with lead plaintiff deadlines approaching. For Badger Meter, the class period is April 18, 2024 to April 16, 2026, and the lead plaintiff deadline is July 27, 2026; the complaint alleges the company pulled forward customer orders to recognize revenue early, concealing weakening demand. For PicS, the class period is January 27, 2026 to June 5, 2026, with a deadline of August 4, 2026; the complaint alleges the offering documents misrepresented credit evaluation procedures and failed to disclose a heightened Stage 3 formation rate and other risks. For Verra Mobility, the class period is February 24, 2026 to May 26, 2026, and the deadline is August 4, 2026; the complaint alleges the company's growth plans were dependent on a contract extension with Avis Budget and that it minimized risks of replacement. For Grail, the class period is May 13, 2025 to February 19, 2026, with a deadline of August 4, 2026; the complaint alleges management's confidence in trial results ignored trendlines suggesting the primary endpoint would be harder to achieve. Investors who suffered losses can contact the firm to discuss their legal rights.

Bernstein Liebhard LLP announced that a securities class action lawsuit has been filed against GRAIL, Inc. on behalf of investors who purchased or acquired GRAIL common stock between May 13, 2025 and February 19, 2026. The lawsuit alleges that defendants made materially false and misleading statements about the company's business operations, growth prospects, and financial stability, causing GRAIL stock to trade at artificially inflated prices. When the truth was disclosed, investors allegedly suffered significant losses. Investors have until August 4, 2026 to file papers to serve as lead plaintiff.

Robbins LLP reminds investors that a class action has been filed on behalf of purchasers of Grail, Inc. securities between May 13, 2025 and February 19, 2026. The lawsuit alleges that Grail misled investors about the likelihood of success for its NHS-Galleri trial in achieving a statistically significant reduction in late-stage cancers. On February 19, 2026, the company reported the trial failed to meet its primary endpoint, causing the stock to drop from $101.53 to $50.21 per share, a decline of approximately 50.55% in one day. Shareholders have until August 4, 2026 to seek lead plaintiff status, though participation is not required to be eligible for recovery. Robbins LLP is handling the case on a contingency fee basis.

Moore Law PLLC is investigating potential claims against the officers and directors of Grail, Inc. The investigation concerns allegations that the company or certain officers made false and misleading statements and failed to disclose material information, artificially inflating Grail’s stock price. On February 20, 2026, Grail’s shares fell from $101.53 to $50.21, a decline of approximately 50.55% in a single trading day, after the alleged misrepresentations became apparent. Shareholders who purchased Grail common stock during the class period may be able to seek monetary damages and other remedies at no cost, as representation is on a contingency fee basis. Investors are encouraged to contact Fletcher Moore at fletcher@fmoorelaw.com.

Grail's multi-cancer early detection test Galleri missed its primary endpoint of reducing late-stage cancers in a 142,000-person NHS trial, but the company is still pursuing FDA approval and insurer coverage. CFO Aaron Freidin said 12-month follow-up data could show more cancers in the control group, supporting the test's benefit. The trial showed a favorable trend for 12 deadly cancers, with episode sensitivity of 54.7% versus 30.7% overall, and positive predictive values of 52% in the NHS study and 60.3% in the PATHFINDER 2 study. Management believes these metrics may encourage insurers to focus on the cost-benefit of detecting those 12 cancers.

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Grail securities between May 13, 2025 and February 19, 2026. The complaint claims defendants misrepresented the likelihood of achieving the primary endpoint in the NHS-Galleri trial, overstated optimism about the study, and made misleading statements based on positive top-line results while ignoring contrary data trends. Investors have until August 4, 2026 to seek lead plaintiff appointment.

Grabar Law Office is investigating claims on behalf of long-term shareholders of Badger Meter, GeneDx Holdings, GRAIL, and Verra Mobility, concerning whether certain officers and directors breached their fiduciary duties. For Badger Meter, a recently filed federal securities class action alleges that the company attributed strong financial performance to sustainable demand-driven growth while results were materially impacted by pull-forward of customer orders, masking weakening demand trends, and the truth emerged through disappointing quarterly announcements in 2025 and 2026 that caused significant stock declines. For GeneDx, a securities fraud class action alleges that executives made false statements about the Fabric acquisition improving financials and creating efficiencies, when they knew of significant problems in Fabric's viability that would negatively impact the business. For GRAIL, a complaint alleges that officers misled investors about the likelihood that the NHS-Galleri cancer screening trial would meet its primary endpoint, and the stock fell more than 50% in a single day after the company announced on February 19, 2026 that the trial failed to achieve a statistically significant reduction in late-stage cancers. For Verra Mobility, a class action alleges that executives created a false impression about revenue outlook and contract renewals while minimizing risks, and the stock declined approximately 71% after the company announced on May 26, 2026 that it received a termination notice from Avis Budget Group and lowered its full-year 2026 financial outlook. Shareholders who purchased or acquired shares prior to specified dates and still hold them can seek corporate reforms and return of funds at no cost.